We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The risk for developing type 2 diabetes increases with ...
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- ...
Alzheimer’s Disease (AD) Patients with APOE4/4 Homozygous Genotype Show High Prevalence of Cerebral Amyloid Angiopathy (CAA) Lesions at Baseline CAA Pathology Increases Risk of Treatment-Induced Brain ...
In this video, Coral Omene, MD, PhD, assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, and program director of Breast Cancer Disparities Research in the division of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results